Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Maze Therapeutics
Biotech
Maze stock plummets after potential 'best-in-class' ph. 2 data
Maze's APOL1 inhibitor MZE829 cut levels of excess protein in the urine by an average of 35.6% among 12 patients after 12 weeks of treatment.
Darren Incorvaia
Mar 25, 2026 10:57am
Metsera, Maze go public with IPOs of $275M, $113M
Jan 31, 2025 7:40am
Maze rolls out map to $131M IPO
Jan 27, 2025 9:45am
Maze charts path through clinical development with planned IPO
Jan 7, 2025 5:40pm
Maze finds its way to $115M series D
Dec 3, 2024 12:42pm
After FTC stalled Sanofi deal, Shionogi bags Maze's Pompe drug
May 10, 2024 5:02am
